Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022.

Journal of sleep research·2024

Same author

Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer.

Breast cancer research and treatment·2024

Same author

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.

EBioMedicine·2022

Same author

Preventing late recurrence in hormone receptor-positive early breast cancer: a review.

European journal of cancer (Oxford, England : 1990)·2022

Same author

Positive role of continuous positive airway pressure for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-19 pneumonia: A single centre experience.

Journal of the Intensive Care Society·2022

Same author

Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.

Breast cancer research and treatment·2022

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Triple-negative breast cancer.

William D Foulkes¹, Ian E Smith, Jorge S Reis-Filho

¹Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada. william.foulkes@mcgill.ca

The New England Journal of Medicine

|November 12, 2010

Summary

This summary is machine-generated.

Triple-negative breast cancer lacks key receptors, often presenting as basal-like. This review explores its origins, molecular features, clinical aspects, and treatment strategies for this aggressive cancer.

Related Experiment Videos

Last Updated: Jun 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression.
TNBC often overlaps with basal-like breast cancer but is not exclusively so.
This subtype presents unique challenges due to its aggressive nature and limited targeted therapy options.

Purpose of the Study:

To provide a comprehensive overview of triple-negative breast cancer.
To elucidate the origins and molecular underpinnings of TNBC.
To detail the clinical characteristics and current treatment modalities for TNBC.

Main Methods:

This review synthesizes existing literature on TNBC.
It analyzes data regarding the molecular profiles and clinical behaviors of TNBC.
Information on therapeutic approaches is compiled from preclinical and clinical studies.

Main Results:

TNBC originates from specific cellular pathways and exhibits distinct molecular signatures.
Clinical presentation varies, with aggressive behavior and higher recurrence rates being common.
Treatment landscape includes chemotherapy, with emerging targeted therapies and immunotherapies.

Conclusions:

Understanding TNBC's multifaceted nature is crucial for effective management.
Further research into its origins and molecular drivers will facilitate the development of novel therapies.
Personalized treatment strategies are essential for improving outcomes in triple-negative breast cancer patients.